Humoral response after a BNT162b2 heterologous third dose of COVID- 19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

• Autores: Montero, Stephanie, Urrunaga-Pastor, Diego, Soto-Becerra, Percy, Cvetkovic Vega, Aleksandar, Guillermo Roman, Martina, Figueroa Montes, Luis, Sagástegui, Arturo A., Alvizuri-Pastor, Sergio, Contreras-Macazana, Roxana M., Apolaya-Segura, Moisés, Díaz-Vélez, Cristian, Maguiña, Jorge L.
• Formato: tesis de grado
• Fecha de Publicación: 2023
• Institución: Seguro Social de Salud
• Repositorio: ESSALUD-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.essalud.gob.pe:20.500.12959/3665
• Enlace del recurso: https://hdl.handle.net/20.500.12959/3665; https://doi.org/10.1016/j.jvacx.2023.100311
• Nivel de acceso: acceso abierto
• Materia: Covid-19; SARS-CoV-2; Vaccination; Vaccine; Booster; Vacunación; Vacuna; Refuerzo; https://purl.org/pe-repo/ocde/ford#3.03.08; https://purl.org/pe-repo/ocde/ford#3.03.09

Background: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes. Limited information is available regarding its effect on heterologous boosting. We aim to evaluate the immunogenicity and reactogenicity of a third booster dose of BNT162b2 following a double BBIBP-CorV regime. Methods: We conducted a cross-sectional study among healthcare providers from several healthcare facilities of the Seguro Social de Salud del Perú - ESSALUD. We included participants two-dose BBIBPCorV vaccinated who presented a three-dose vaccination card at least 21 days passed since the vaccinees received their third dose and were willing to provide written informed consent. Antibodies were determined using LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin Inc., Stillwater, USA). Factors potentially associated with immunogenicity, and adverse events, were considered. We used a multivariable fractional polynomial modeling approach to estimate the association between anti-SARS-CoV-2 IgG antibodies’ geometric mean (GM) ratios and related predictors. Results: We included 595 subjects receiving a third dose with a median (IQR) age of 46 [37,54], from which 40% reported previous SARS-CoV-2 infection. The overall geometric mean (IQR) of anti-SARSCoV- 2 IgG antibodies was 8,410 (5,115 – 13,000) BAU/mL. Prior SARS-CoV-2 history and full/part-time in-person working modality were significantly associated with greater GM. Conversely, time from boosting to IgG measure was associated with lower GM levels. We found 81% of reactogenicity in the study population; younger age and being a nurse were associated with a lower incidence of adverse events. Conclusions: Among healthcare providers, a booster dose of BNT162b2 following a full BBIBP-CorV regime provided high humoral immune protection. Thus, SARS-CoV-2 previous exposure and working in person displayed as determinants that increase anti-SARS-CoV-2 IgG antibodies.